Target identification of $\textit{Mycobacterium tuberculosis phenotypic}$ hits using a concerted chemogenomic, biophysical and structural approach
Authors
Mugumbate, G
Blaszczyk, Michal
Sabbah, M
Papadatos, G
Lelievre, J
Ballell, L
Barros, D
Overington, JP
Publication Date
2017-09-26Journal Title
Frontiers in Pharmacology
ISSN
1663-9812
Publisher
Frontiers Media
Volume
8
Number
681
Language
English
Type
Article
This Version
VoR
Metadata
Show full item recordCitation
Mugumbate, G., Silva E Costa Mendes, V., Blaszczyk, M., Sabbah, M., Papadatos, G., Lelievre, J., Ballell, L., et al. (2017). Target identification of $\textit{Mycobacterium tuberculosis phenotypic}$ hits using a concerted chemogenomic, biophysical and structural approach. Frontiers in Pharmacology, 8 (681)https://doi.org/10.3389/fphar.2017.00681
Abstract
Mycobacterium phenotypic hits are a good reservoir for new chemotypes for the treatment of tuberculosis. However, the absence
of defined molecular targets and modes of action could lead to failure in drug development. Therefore, a combination of
ligand-based and structure-based chemogenomic approaches followed by biophysical and biochemical validation have been used to
identify targets for Mycobacterium tuberculosis phenotypic hits. Our approach identified EthR and InhA as targets for several hits,
with some showing dual activity against these proteins. From the 35 predicted EthR inhibitors, eight exhibited an IC50 below 50
μM against M. tuberculosis EthR and three were confirmed to be also simultaneously active against InhA. Further hit validation was
performed using X-ray crystallography yielding eight new crystal structures of EthR inhibitors. Although the EthR inhibitors attain
their activity against M. tuberculosis by hitting yet undefined targets, these results provide new lead compounds that could be
further developed to be used to potentiate the effect of EthA activated pro-drugs, such as ethionamide, thus enhancing their
bactericidal effect.
Keywords
mycobacterium tuberculosis, tuberculosis, phenotypic hits, target identification, in silico target prediction, target deconvolution, drug resistance, EthR, InhA
Relationships
Is supplemented by: https://doi.org/10.17863/CAM.13199
Sponsorship
GM is grateful to the European Molecular Biology Laboratory and Marie Sklodowska-Curie Actions for funding this work. VM and MB
acknowledge Bill & Melinda Gates Foundation [subcontract by the Foundation for the National Institutes of Health (NIH)]
(OPP1024021). VM and MS acknowledge the European Community’s Seventh Framework Programme [grant number 260872]. GP
would like to acknowledge the Wellcome Trust and the European Molecular Biology Laboratory for funding. JPO was funded by the
member nation states of the European Molecular Biology Laboratory. TLB acknowledges The Wellcome Trust for funding and
support (grant number 200814/Z/16/Z).
Funder references
EC FP7 CP (260872)
MRC (MR/M026302/1)
Medical Research Council (MR/N501864/1)
WELLCOME TRUST (200814/Z/16/Z)
Embargo Lift Date
2100-01-01
Identifiers
External DOI: https://doi.org/10.3389/fphar.2017.00681
This record's URL: https://www.repository.cam.ac.uk/handle/1810/271509
Recommended or similar items
The following licence files are associated with this item: